Literature DB >> 34374852

Blueberry extract improves redox balance and functional parameters in the right ventricle from rats with pulmonary arterial hypertension.

Patrick Türck1,2, Isadora Schein Salvador3, Cristina Campos-Carraro3,4, Vanessa Ortiz3,4, Alan Bahr3,4, Michael Andrades5, Adriane Belló-Klein3,4, Alex Sander da Rosa Araujo3,4.   

Abstract

PURPOSE: Pulmonary arterial hypertension (PAH) is a disease characterized by increased pulmonary vascular resistance and right ventricle (RV) failure. In this context, oxidative stress is an essential element contributing to PAH's pathophysiology. Thus, blueberry (BB), which has a high antioxidant capacity, emerges as a natural therapeutic approach in PAH. This work evaluated the effect of BB extract on redox balance in RV in a PAH's animal model.
METHODS: Male Wistar rats (200 ± 20 g) (n = 72) were randomized into eight groups: control (CTR); monocrotaline (MCT); CTR and MCT treated at doses of 50, 100, and 200 mg/kg BB. PAH was induced by administration of MCT (60 mg/kg, intraperitoneal). Rats were treated with BB orally for 5 weeks (2 weeks before monocrotaline and 3 weeks after monocrotaline injection). On day 35, rats were submitted to echocardiography and catheterization, then euthanasia and RV harvesting for biochemical analyses.
RESULTS: RV hypertrophy, observed in the MCT groups, was reduced with BB treatment. MCT elevated RV systolic pressure and pressure/time derivatives, while the intervention with BB decreased these parameters. PAH decreased RV output and pulmonary artery outflow acceleration/ejection time ratio, while increased RV diameters, parameters restored by BB treatment. Animals from the MCT group showed elevated lipid peroxidation and NADPH oxidase activity, outcomes attenuated in animals treated with BB, which also led to increased catalase activity.
CONCLUSION: Treatment with BB partially mitigated PAH, which could be associated with improvement of RV redox state. Such findings constitute an advance in the investigation of the role of BB extract in chronic progressive cardiovascular diseases that involve the redox balance, such as PAH.
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Blueberry; Monocrotaline; Oxidative stress; Pulmonary hypertension; Right ventricle

Mesh:

Substances:

Year:  2021        PMID: 34374852     DOI: 10.1007/s00394-021-02642-9

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  48 in total

1.  Oxidative stress is associated with increased pulmonary artery systolic pressure in humans.

Authors:  Nima Ghasemzadeh; Riyaz S Patel; Danny J Eapen; Emir Veledar; Hatem Al Kassem; Pankaj Manocha; Mohamed Khayata; A Maziar Zafari; Laurence Sperling; Dean P Jones; Arshed A Quyyumi
Journal:  Hypertension       Date:  2014-03-10       Impact factor: 10.190

2.  Contribution of oxidative stress to pulmonary arterial hypertension.

Authors:  Vincent G Demarco; Adam T Whaley-Connell; James R Sowers; Javad Habibi; Kevin C Dellsperger
Journal:  World J Cardiol       Date:  2010-10-26

3.  Role of inflammation, oxidative stress, and autonomic nervous system activation during the development of right and left cardiac remodeling in experimental pulmonary arterial hypertension.

Authors:  A Zimmer; R B Teixeira; J H P Bonetto; A C Bahr; P Türck; A L de Castro; C Campos-Carraro; F Visioli; T R Fernandes-Piedras; K R Casali; C M C Scassola; G Baldo; A S Araujo; P Singal; A Belló-Klein
Journal:  Mol Cell Biochem       Date:  2019-11-14       Impact factor: 3.396

4.  Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice.

Authors:  S F Yet; M A Perrella; M D Layne; C M Hsieh; K Maemura; L Kobzik; P Wiesel; H Christou; S Kourembanas; M E Lee
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

5.  Oxidative-stress biomarkers in patients with pulmonary hypertension.

Authors:  Graziela S Reis; Viviane S Augusto; Ana Paula C Silveira; Alceu A Jordão; José Baddini-Martinez; Omero Poli Neto; Alfredo José Rodrigues; Paulo Roberto B Evora
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

6.  N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats.

Authors:  Marie-Camille Chaumais; Benoît Ranchoux; David Montani; Peter Dorfmüller; Ly Tu; Florence Lecerf; Nicolas Raymond; Christophe Guignabert; Laura Price; Gérald Simonneau; Sylvia Cohen-Kaminsky; Marc Humbert; Frédéric Perros
Journal:  Respir Res       Date:  2014-06-14

7.  Oxidative profiling of the failing right heart in rats with pulmonary hypertension.

Authors:  Xinhong Wang; Nataliia V Shults; Yuichiro J Suzuki
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

Review 8.  Oxidative Stress and Its Implications in the Right Ventricular Remodeling Secondary to Pulmonary Hypertension.

Authors:  Matthew Mikhael; Christian Makar; Amir Wissa; Trixie Le; Mansoureh Eghbali; Soban Umar
Journal:  Front Physiol       Date:  2019-09-24       Impact factor: 4.566

9.  Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.

Authors:  Marc Humbert; Christophe Guignabert; Sébastien Bonnet; Peter Dorfmüller; James R Klinger; Mark R Nicolls; Andrea J Olschewski; Soni S Pullamsetti; Ralph T Schermuly; Kurt R Stenmark; Marlene Rabinovitch
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

10.  Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.

Authors:  Anton Vonk Noordegraaf; Kelly Marie Chin; François Haddad; Paul M Hassoun; Anna R Hemnes; Susan Roberta Hopkins; Steven Mark Kawut; David Langleben; Joost Lumens; Robert Naeije
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

View more
  1 in total

Review 1.  Target Nuclear Factor Erythroid 2-Related Factor 2 in Pulmonary Hypertension: Molecular Insight into Application.

Authors:  Yuhan Qin; Yong Qiao; Dong Wang; Linqing Li; Mingkang Li; Gaoliang Yan; Chengchun Tang
Journal:  Oxid Med Cell Longev       Date:  2022-06-06       Impact factor: 7.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.